F A Distler1, S Pahernik2, G Gakis3, G Hutterer4, S Lebentrau5, M Rink6, P Nuhn7, S Brookman-May8, M Burger9, C Gratzke10, I Wolff11, M May12. 1. Department of Urology, Klinikum Nuremberg, Paracelsus Medical University Nuremberg, Nuremberg, Germany. florian.distler@klinikum-nuernberg.de. 2. Department of Urology, Klinikum Nuremberg, Paracelsus Medical University Nuremberg, Nuremberg, Germany. 3. Department of Urology and Pediatric Urology, University Hospital of Würzburg, Würzburg, Germany. 4. Department of Urology, Medical University of Graz, Graz, Austria. 5. Department of Urology, Brandenburg Medical School Theodor Fontane, Ruppiner Kliniken, Neuruppin, Germany. 6. Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 7. Department of Urology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany. 8. Department of Urology, Großhadern, LMU Munich, Munich, Germany. 9. Department of Urology, St. Josef-Hospital Regensburg, Medical University Regensburg, Regensburg, Germany. 10. Department of Urology, University of Freiburg, Freiburg, Germany. 11. Department of Urology, University Medicine Greifswald, Greifswald, Germany. 12. Department of Urology, St. Elisabeth-Hospital Straubing, Straubing, Germany.
Abstract
OBJECTIVES: To validate the adherence of urologists to chemotherapy recommendations given in the EAU guidelines on PeCa. The European Association of Urology (EAU) guidelines on penile cancer (PeCa) are predominantly based on retrospective studies with low level of evidence. MATERIALS AND METHODS: A 14-item-survey addressing general issues of PeCa treatment was developed and sent to 45 European hospitals. 557 urologists participated in the survey of which 43.5%, 19.3%, and 37.2% were in-training, certified, and in leading positions, respectively. Median response rate among participating departments was 85.7% (IQR 75-94%). Three of 14 questions addressed clinical decisions on neoadjuvant, adjuvant, and palliative chemotherapy. Survey results were analyzed by bootstrap-adjusted multivariate logistic-regression-analysis to identify predictors for chemotherapy recommendations consistent with the guidelines. RESULTS: Neoadjuvant, adjuvant, and palliative chemotherapy was recommended according to EAU guidelines in 21%, 26%, and 48%, respectively. For neoadjuvant chemotherapy, urologists holding leading positions or performing chemotherapy were more likely to recommend guideline-consistent treatment (OR 1.85 and 1.92 with p(bootstrap) = 0.007 and 0.003, respectively). Supporting resources (i.e., guidelines, textbooks) were used by 23% of survey participants and significantly improved consistency between treatment recommendations and Guideline recommendations in all chemotherapy settings (p(bootstrap) = 0.010-0.001). Department size and university center status were no significant predictors for all three endpoints. CONCLUSIONS: In this study, we found a very low rate of adherence to the EAU guidelines on systemic treatment for PeCa. Further investigations are needed to clarify whether this missing adherence is a consequence of limited individual knowledge level or of the low grade of guideline recommendations.
OBJECTIVES: To validate the adherence of urologists to chemotherapy recommendations given in the EAU guidelines on PeCa. The European Association of Urology (EAU) guidelines on penile cancer (PeCa) are predominantly based on retrospective studies with low level of evidence. MATERIALS AND METHODS: A 14-item-survey addressing general issues of PeCa treatment was developed and sent to 45 European hospitals. 557 urologists participated in the survey of which 43.5%, 19.3%, and 37.2% were in-training, certified, and in leading positions, respectively. Median response rate among participating departments was 85.7% (IQR 75-94%). Three of 14 questions addressed clinical decisions on neoadjuvant, adjuvant, and palliative chemotherapy. Survey results were analyzed by bootstrap-adjusted multivariate logistic-regression-analysis to identify predictors for chemotherapy recommendations consistent with the guidelines. RESULTS: Neoadjuvant, adjuvant, and palliative chemotherapy was recommended according to EAU guidelines in 21%, 26%, and 48%, respectively. For neoadjuvant chemotherapy, urologists holding leading positions or performing chemotherapy were more likely to recommend guideline-consistent treatment (OR 1.85 and 1.92 with p(bootstrap) = 0.007 and 0.003, respectively). Supporting resources (i.e., guidelines, textbooks) were used by 23% of survey participants and significantly improved consistency between treatment recommendations and Guideline recommendations in all chemotherapy settings (p(bootstrap) = 0.010-0.001). Department size and university center status were no significant predictors for all three endpoints. CONCLUSIONS: In this study, we found a very low rate of adherence to the EAU guidelines on systemic treatment for PeCa. Further investigations are needed to clarify whether this missing adherence is a consequence of limited individual knowledge level or of the low grade of guideline recommendations.
Authors: Lance C Pagliaro; Dallas L Williams; Danai Daliani; Michael B Williams; William Osai; Michael Kincaid; Sijin Wen; Peter F Thall; Curtis A Pettaway Journal: J Clin Oncol Date: 2010-07-12 Impact factor: 44.544
Authors: Rodolphe Thuret; Maxine Sun; Giovanni Lughezzani; Lars Budaus; Daniel Liberman; Firas Abdollah; Monica Morgan; Rupinder Johal; Claudio Jeldres; Mathieu Latour; Shahrokh F Shariat; François Iborra; Jacques Guiter; Jean-Jacques Patard; Paul Perrotte; Pierre I Karakiewicz Journal: Ann Surg Oncol Date: 2010-09-14 Impact factor: 5.344
Authors: Nicola Nicolai; Laura Maria Sangalli; Andrea Necchi; Patrizia Giannatempo; Anna Maria Paganoni; Maurizio Colecchia; Luigi Piva; Mario Achille Catanzaro; Davide Biasoni; Silvia Stagni; Tullio Torelli; Daniele Raggi; Elena Faré; Giorgio Pizzocaro; Roberto Salvioni Journal: Clin Genitourin Cancer Date: 2015-08-06 Impact factor: 2.872
Authors: Luca Cindolo; Philippe E Spiess; Maida Bada; Juan J Chipollini; Peter Nyirády; Paolo Chiodini; Judith Varga; Pasquale Ditonno; Michele Battaglia; Cosimo De Nunzio; Giorgia Tema; Alessandro Veccia; Alessandro Antonelli; Gennaro Musi; Ottavio De Cobelli; Andrea Conti; Salvatore Micali; Mario Álvarez-Maestro; José Quesada Olarte; Erico Diogenes; Marcos Venicio Alves Lima; Andrew Tracey; Georgi Guruli; Riccardo Autorino; Petros Sountoulides; Luigi Schips Journal: World J Urol Date: 2018-10-30 Impact factor: 4.226
Authors: Maximilian Pallauf; Marie C Hempel; Marie C Hupe; Matthias May; Marlene Haccius; Dorothea Weckermann; Steffen Lebentrau; Bernd Hoschke; Ulrike Necknig; Jesco Pfitzenmaier; Lukas Manka; Philipp Nuhn; Peter Törzsök; Lukas Lusuardi; Axel S Merseburger Journal: Adv Ther Date: 2020-10-10 Impact factor: 3.845
Authors: Steffen Lebentrau; Gamal Anton Wakileh; Martin Schostak; Hans-Peter Schmid; Rodrigo Suarez-Ibarrola; Axel S Merseburger; Georg C Hutterer; Ulrike H Necknig; Michael Rink; Martin Bögemann; Luis Alex Kluth; Armin Pycha; Maximilian Burger; Sabine D Brookman-May; Johannes Bründl; Matthias May Journal: Front Oncol Date: 2021-11-29 Impact factor: 6.244
Authors: Silvia Regina Rogatto; Igor Tsaur; Anita Thomas; Luisa Matos do Canto Alvim; Claudia Aparecida Rainho; Eva Juengel; Roman Alexander Blaheta; Philippe E Spiess Journal: Transl Androl Urol Date: 2021-10